 Edwin deZoeten
Concepts (331)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Inflammatory Bowel Diseases | 15 | 2023 | 284 | 4.250 |
Why?
| | T-Lymphocytes, Regulatory | 14 | 2023 | 339 | 3.600 |
Why?
| | Colitis | 12 | 2021 | 223 | 3.280 |
Why?
| | Crohn Disease | 8 | 2023 | 196 | 1.750 |
Why?
| | HSP90 Heat-Shock Proteins | 3 | 2014 | 43 | 1.220 |
Why?
| | Forkhead Transcription Factors | 9 | 2023 | 170 | 1.200 |
Why?
| | Inflammation | 9 | 2023 | 2480 | 1.140 |
Why?
| | Ileitis | 3 | 2017 | 26 | 1.110 |
Why?
| | CD4-Positive T-Lymphocytes | 5 | 2018 | 959 | 0.940 |
Why?
| | Immunity, Mucosal | 2 | 2023 | 84 | 0.870 |
Why?
| | Immune System Diseases | 1 | 2023 | 32 | 0.850 |
Why?
| | Gastroenterologists | 1 | 2023 | 18 | 0.830 |
Why?
| | Diarrhea | 2 | 2017 | 171 | 0.830 |
Why?
| | Adenosine Triphosphatases | 2 | 2014 | 153 | 0.820 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2023 | 25 | 0.810 |
Why?
| | Colitis, Ulcerative | 1 | 2023 | 105 | 0.770 |
Why?
| | Eosinophilia | 4 | 2019 | 186 | 0.760 |
Why?
| | Clostridium Infections | 2 | 2022 | 56 | 0.750 |
Why?
| | Colon | 4 | 2018 | 233 | 0.690 |
Why?
| | Enteral Nutrition | 1 | 2020 | 160 | 0.650 |
Why?
| | Fecal Microbiota Transplantation | 2 | 2022 | 14 | 0.630 |
Why?
| | Systems Biology | 1 | 2019 | 54 | 0.630 |
Why?
| | CCAAT-Enhancer-Binding Protein-beta | 1 | 2018 | 32 | 0.620 |
Why?
| | Colonic Diseases | 1 | 2018 | 25 | 0.600 |
Why?
| | Lactoferrin | 1 | 2017 | 28 | 0.580 |
Why?
| | DNA, Neoplasm | 4 | 2002 | 157 | 0.560 |
Why?
| | Mice | 26 | 2023 | 14872 | 0.520 |
Why?
| | Mice, Inbred C57BL | 19 | 2018 | 4694 | 0.520 |
Why?
| | Intestinal Mucosa | 7 | 2018 | 532 | 0.510 |
Why?
| | Precision Medicine | 1 | 2019 | 337 | 0.510 |
Why?
| | Histone Deacetylases | 5 | 2012 | 195 | 0.500 |
Why?
| | Cytoplasm | 3 | 2013 | 255 | 0.500 |
Why?
| | Mice, Knockout | 10 | 2023 | 2570 | 0.460 |
Why?
| | Novobiocin | 1 | 2014 | 5 | 0.460 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2022 | 1140 | 0.460 |
Why?
| | Melanoma, Experimental | 5 | 2002 | 89 | 0.450 |
Why?
| | Phenotype | 3 | 2019 | 2797 | 0.450 |
Why?
| | Anus Diseases | 1 | 2013 | 7 | 0.440 |
Why?
| | Cell Nucleus | 2 | 2014 | 554 | 0.430 |
Why?
| | Fistula | 1 | 2013 | 26 | 0.430 |
Why?
| | Enzyme Inhibitors | 2 | 2014 | 750 | 0.430 |
Why?
| | Abscess | 1 | 2013 | 72 | 0.420 |
Why?
| | Anal Canal | 1 | 2013 | 84 | 0.420 |
Why?
| | Animals | 28 | 2023 | 31709 | 0.370 |
Why?
| | Infliximab | 4 | 2023 | 94 | 0.360 |
Why?
| | Fibroblasts | 6 | 2002 | 838 | 0.360 |
Why?
| | Cancer Vaccines | 4 | 2001 | 137 | 0.350 |
Why?
| | Adoptive Transfer | 3 | 2014 | 195 | 0.340 |
Why?
| | Heat Shock Transcription Factors | 2 | 2023 | 17 | 0.330 |
Why?
| | Dextran Sulfate | 3 | 2014 | 70 | 0.320 |
Why?
| | Interleukin-2 | 6 | 2019 | 413 | 0.320 |
Why?
| | Biomarkers | 1 | 2019 | 3408 | 0.320 |
Why?
| | Proprotein Convertases | 1 | 2008 | 14 | 0.320 |
Why?
| | Sucrase-Isomaltase Complex | 1 | 2008 | 1 | 0.310 |
Why?
| | Carbohydrate Metabolism, Inborn Errors | 1 | 2008 | 2 | 0.310 |
Why?
| | Child | 10 | 2023 | 18422 | 0.310 |
Why?
| | Lymphocyte Activation | 3 | 2014 | 1037 | 0.310 |
Why?
| | Biological Therapy | 1 | 2008 | 26 | 0.310 |
Why?
| | Humans | 34 | 2023 | 114709 | 0.290 |
Why?
| | Histone Deacetylase Inhibitors | 4 | 2011 | 198 | 0.280 |
Why?
| | Research Design | 1 | 2013 | 928 | 0.280 |
Why?
| | Interleukin-10 | 4 | 2018 | 299 | 0.280 |
Why?
| | Biomedical Research | 1 | 2013 | 585 | 0.280 |
Why?
| | Repressor Proteins | 1 | 2009 | 366 | 0.270 |
Why?
| | Immunotherapy, Adoptive | 1 | 2008 | 184 | 0.260 |
Why?
| | Transfection | 5 | 2002 | 866 | 0.260 |
Why?
| | DNA-Binding Proteins | 1 | 2013 | 1314 | 0.260 |
Why?
| | CTLA-4 Antigen | 2 | 2021 | 76 | 0.260 |
Why?
| | Remission Induction | 2 | 2020 | 233 | 0.250 |
Why?
| | Flow Cytometry | 5 | 2017 | 1083 | 0.250 |
Why?
| | Transcription Factors | 1 | 2013 | 1528 | 0.240 |
Why?
| | Autoimmune Diseases | 1 | 2008 | 382 | 0.240 |
Why?
| | Mice, Transgenic | 4 | 2023 | 1950 | 0.240 |
Why?
| | H-2 Antigens | 3 | 2001 | 110 | 0.230 |
Why?
| | Cell Proliferation | 6 | 2019 | 2187 | 0.230 |
Why?
| | Genetic Therapy | 3 | 2002 | 257 | 0.220 |
Why?
| | Heat-Shock Response | 1 | 2023 | 46 | 0.220 |
Why?
| | Adalimumab | 1 | 2023 | 44 | 0.210 |
Why?
| | Retrospective Studies | 7 | 2022 | 12556 | 0.210 |
Why?
| | Cytokines | 5 | 2018 | 1841 | 0.210 |
Why?
| | Ileum | 3 | 2023 | 90 | 0.210 |
Why?
| | Abdominal Abscess | 1 | 2022 | 25 | 0.200 |
Why?
| | Age of Onset | 1 | 2023 | 446 | 0.200 |
Why?
| | Histocompatibility Antigens Class I | 2 | 2002 | 172 | 0.190 |
Why?
| | Vaccines, DNA | 2 | 1999 | 29 | 0.190 |
Why?
| | Intestines | 2 | 2023 | 326 | 0.190 |
Why?
| | Blotting, Western | 4 | 2015 | 1147 | 0.190 |
Why?
| | Haploinsufficiency | 1 | 2021 | 42 | 0.180 |
Why?
| | Practice Guidelines as Topic | 1 | 2008 | 1395 | 0.180 |
Why?
| | Pediatrics | 1 | 2008 | 981 | 0.180 |
Why?
| | Graft vs Host Disease | 1 | 2022 | 212 | 0.180 |
Why?
| | Infant | 4 | 2020 | 7964 | 0.170 |
Why?
| | Neoplasms, Experimental | 1 | 2001 | 151 | 0.170 |
Why?
| | Diagnosis, Differential | 2 | 2018 | 1342 | 0.170 |
Why?
| | Feces | 2 | 2022 | 373 | 0.170 |
Why?
| | Celiac Disease | 1 | 2022 | 264 | 0.160 |
Why?
| | Immunotherapy | 2 | 2002 | 474 | 0.160 |
Why?
| | Interleukin-2 Receptor beta Subunit | 1 | 2019 | 19 | 0.160 |
Why?
| | Recurrence | 2 | 2022 | 935 | 0.160 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 1999 | 64 | 0.160 |
Why?
| | Integrins | 1 | 2019 | 79 | 0.160 |
Why?
| | Disease Progression | 2 | 2019 | 2381 | 0.160 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2017 | 314 | 0.160 |
Why?
| | Parents | 2 | 2020 | 1186 | 0.160 |
Why?
| | Colonoscopy | 2 | 2017 | 204 | 0.160 |
Why?
| | Th17 Cells | 1 | 2018 | 58 | 0.150 |
Why?
| | Fibrosis | 2 | 2023 | 453 | 0.150 |
Why?
| | Receptor, Cannabinoid, CB2 | 1 | 2017 | 3 | 0.150 |
Why?
| | Th1 Cells | 1 | 2018 | 123 | 0.150 |
Why?
| | Immunoglobulin A | 2 | 2022 | 166 | 0.150 |
Why?
| | Cells, Cultured | 4 | 2018 | 3886 | 0.150 |
Why?
| | Antibodies, Monoclonal | 3 | 2013 | 1264 | 0.140 |
Why?
| | Stomach | 1 | 2017 | 102 | 0.140 |
Why?
| | Intubation, Gastrointestinal | 1 | 2017 | 56 | 0.140 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2022 | 520 | 0.140 |
Why?
| | Attitude to Health | 1 | 2020 | 406 | 0.140 |
Why?
| | Killer Cells, Natural | 2 | 2019 | 380 | 0.140 |
Why?
| | Gene Deletion | 1 | 2018 | 356 | 0.140 |
Why?
| | Gastrostomy | 1 | 2017 | 91 | 0.140 |
Why?
| | Jurkat Cells | 2 | 2014 | 128 | 0.140 |
Why?
| | Disease Models, Animal | 5 | 2018 | 3535 | 0.140 |
Why?
| | Gene Expression Regulation | 4 | 2014 | 2320 | 0.140 |
Why?
| | Chronic Disease | 4 | 2022 | 1578 | 0.130 |
Why?
| | Signal Transduction | 3 | 2019 | 4516 | 0.130 |
Why?
| | Adrenal Cortex Hormones | 1 | 2019 | 497 | 0.130 |
Why?
| | Mice, Inbred C3H | 5 | 2007 | 239 | 0.130 |
Why?
| | Genetic Predisposition to Disease | 1 | 2023 | 2087 | 0.130 |
Why?
| | Interleukin-33 | 1 | 2015 | 38 | 0.120 |
Why?
| | Molecular Sequence Data | 2 | 2011 | 2785 | 0.120 |
Why?
| | Receptor, Adenosine A2B | 1 | 2015 | 32 | 0.120 |
Why?
| | Marijuana Use | 1 | 2018 | 167 | 0.120 |
Why?
| | Infant, Newborn | 2 | 2023 | 5047 | 0.120 |
Why?
| | Fatty Acids, Omega-6 | 1 | 2015 | 45 | 0.120 |
Why?
| | Marijuana Smoking | 1 | 2018 | 224 | 0.120 |
Why?
| | Genomics | 1 | 2019 | 635 | 0.120 |
Why?
| | Ikaros Transcription Factor | 1 | 2014 | 18 | 0.120 |
Why?
| | Adolescent | 5 | 2018 | 17855 | 0.110 |
Why?
| | Recombinant Proteins | 1 | 2017 | 1230 | 0.110 |
Why?
| | Female | 12 | 2018 | 59523 | 0.110 |
Why?
| | NFATC Transcription Factors | 1 | 2014 | 78 | 0.110 |
Why?
| | Motivation | 1 | 2018 | 494 | 0.110 |
Why?
| | Tumor Necrosis Factor Ligand Superfamily Member 13 | 1 | 2013 | 3 | 0.110 |
Why?
| | Transmembrane Activator and CAML Interactor Protein | 1 | 2013 | 3 | 0.110 |
Why?
| | Fissure in Ano | 1 | 2013 | 2 | 0.110 |
Why?
| | Pruritus Ani | 1 | 2013 | 2 | 0.110 |
Why?
| | Suppuration | 1 | 2013 | 8 | 0.110 |
Why?
| | T-Lymphocytes | 2 | 2019 | 1737 | 0.110 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2019 | 663 | 0.110 |
Why?
| | Transcription Factor RelA | 1 | 2014 | 82 | 0.110 |
Why?
| | Hydroxamic Acids | 2 | 2011 | 80 | 0.110 |
Why?
| | Plasma Cells | 1 | 2013 | 56 | 0.110 |
Why?
| | Immunosuppressive Agents | 1 | 2017 | 646 | 0.110 |
Why?
| | Enterocolitis | 1 | 2013 | 33 | 0.110 |
Why?
| | Leukocyte Common Antigens | 1 | 2013 | 75 | 0.100 |
Why?
| | Lactams, Macrocyclic | 1 | 2013 | 46 | 0.100 |
Why?
| | Interleukin-12 Subunit p40 | 1 | 2012 | 7 | 0.100 |
Why?
| | Fecal Incontinence | 1 | 2013 | 73 | 0.100 |
Why?
| | Benzoquinones | 1 | 2013 | 44 | 0.100 |
Why?
| | MicroRNAs | 1 | 2018 | 600 | 0.100 |
Why?
| | alpha 1-Antitrypsin | 1 | 2013 | 103 | 0.100 |
Why?
| | Enzyme Activation | 1 | 2014 | 785 | 0.100 |
Why?
| | Glutathione Transferase | 1 | 2012 | 93 | 0.100 |
Why?
| | Wet Macular Degeneration | 1 | 2012 | 32 | 0.100 |
Why?
| | Heart Transplantation | 1 | 2017 | 665 | 0.090 |
Why?
| | Male | 10 | 2018 | 55609 | 0.090 |
Why?
| | Protein Transport | 1 | 2013 | 395 | 0.090 |
Why?
| | Histone Deacetylase 6 | 1 | 2011 | 19 | 0.090 |
Why?
| | Consent Forms | 1 | 2011 | 11 | 0.090 |
Why?
| | Transplantation Tolerance | 1 | 2011 | 30 | 0.090 |
Why?
| | Consensus | 1 | 2013 | 539 | 0.090 |
Why?
| | Treatment Outcome | 3 | 2022 | 9088 | 0.090 |
Why?
| | Gene Targeting | 1 | 2011 | 75 | 0.090 |
Why?
| | Microarray Analysis | 1 | 2011 | 118 | 0.090 |
Why?
| | Mice, Inbred BALB C | 2 | 2011 | 1144 | 0.090 |
Why?
| | Computers | 1 | 2011 | 60 | 0.090 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2012 | 249 | 0.090 |
Why?
| | Immunoprecipitation | 1 | 2011 | 151 | 0.090 |
Why?
| | Anilides | 1 | 2011 | 67 | 0.090 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 923 | 0.090 |
Why?
| | Autoimmunity | 2 | 2019 | 813 | 0.090 |
Why?
| | Epigenesis, Genetic | 2 | 2012 | 521 | 0.090 |
Why?
| | Informed Consent | 1 | 2011 | 161 | 0.080 |
Why?
| | Tumor Cells, Cultured | 3 | 2001 | 850 | 0.080 |
Why?
| | Antigens, Neoplasm | 3 | 2001 | 222 | 0.080 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2009 | 61 | 0.080 |
Why?
| | Epithelial Cells | 1 | 2015 | 951 | 0.080 |
Why?
| | Hemorrhage | 1 | 2013 | 620 | 0.080 |
Why?
| | Child, Preschool | 3 | 2017 | 9119 | 0.080 |
Why?
| | Epitopes | 2 | 2002 | 435 | 0.080 |
Why?
| | RNA, Messenger | 3 | 2013 | 2553 | 0.080 |
Why?
| | Indoles | 1 | 2011 | 304 | 0.080 |
Why?
| | Retroviridae | 1 | 2008 | 90 | 0.080 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2008 | 66 | 0.080 |
Why?
| | Mutation | 1 | 2019 | 3346 | 0.080 |
Why?
| | Homeostasis | 1 | 2012 | 573 | 0.080 |
Why?
| | Pediatric Obesity | 1 | 2015 | 489 | 0.080 |
Why?
| | Endoscopy | 1 | 2011 | 246 | 0.080 |
Why?
| | Oxazolone | 1 | 2008 | 5 | 0.080 |
Why?
| | Picrates | 1 | 2008 | 4 | 0.080 |
Why?
| | Trinitrobenzenesulfonic Acid | 1 | 2008 | 9 | 0.080 |
Why?
| | Growth | 1 | 2008 | 55 | 0.080 |
Why?
| | Bystander Effect | 1 | 2008 | 15 | 0.080 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 993 | 0.080 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2008 | 353 | 0.070 |
Why?
| | Cohort Studies | 1 | 2017 | 4895 | 0.070 |
Why?
| | DNA Methylation | 1 | 2012 | 496 | 0.070 |
Why?
| | Pain | 1 | 2013 | 705 | 0.070 |
Why?
| | Graft Rejection | 1 | 2011 | 513 | 0.070 |
Why?
| | Transplantation Immunology | 1 | 2007 | 30 | 0.070 |
Why?
| | Immunologic Factors | 1 | 2009 | 220 | 0.070 |
Why?
| | Immunization | 2 | 2001 | 397 | 0.070 |
Why?
| | Cell Line | 3 | 2002 | 2637 | 0.070 |
Why?
| | Cell Survival | 1 | 2009 | 1021 | 0.070 |
Why?
| | Antigens, CD | 1 | 2008 | 442 | 0.070 |
Why?
| | Hypoxia | 1 | 2012 | 958 | 0.070 |
Why?
| | Aged | 1 | 2023 | 19074 | 0.060 |
Why?
| | Macrophages | 1 | 2012 | 1263 | 0.060 |
Why?
| | Recombinant Fusion Proteins | 1 | 2008 | 616 | 0.060 |
Why?
| | Chromatin | 1 | 2008 | 428 | 0.060 |
Why?
| | Homeodomain Proteins | 1 | 2008 | 463 | 0.060 |
Why?
| | Anti-Inflammatory Agents | 1 | 2008 | 447 | 0.060 |
Why?
| | Amino Acid Sequence | 1 | 2008 | 1982 | 0.060 |
Why?
| | Evidence-Based Medicine | 1 | 2008 | 668 | 0.060 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2008 | 615 | 0.060 |
Why?
| | Transplantation, Homologous | 2 | 2022 | 377 | 0.060 |
Why?
| | Cell Movement | 1 | 2008 | 869 | 0.060 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2008 | 1214 | 0.050 |
Why?
| | Duodenum | 1 | 2022 | 62 | 0.050 |
Why?
| | Cellulitis | 1 | 2022 | 45 | 0.050 |
Why?
| | Transglutaminases | 1 | 2022 | 142 | 0.050 |
Why?
| | Necrosis | 1 | 2022 | 211 | 0.050 |
Why?
| | Acute Disease | 2 | 2015 | 911 | 0.050 |
Why?
| | Age Factors | 1 | 2008 | 2894 | 0.050 |
Why?
| | Promoter Regions, Genetic | 2 | 2018 | 1131 | 0.050 |
Why?
| | Mice, Inbred DBA | 1 | 2001 | 174 | 0.040 |
Why?
| | T-Lymphocytes, Cytotoxic | 2 | 1998 | 154 | 0.040 |
Why?
| | Cell Differentiation | 1 | 2007 | 1701 | 0.040 |
Why?
| | Cell Transplantation | 1 | 1999 | 36 | 0.040 |
Why?
| | Cell Compartmentation | 1 | 2019 | 51 | 0.040 |
Why?
| | Survival Analysis | 2 | 1999 | 1211 | 0.040 |
Why?
| | Interleukin-15 | 1 | 2019 | 74 | 0.040 |
Why?
| | Carboxylic Ester Hydrolases | 1 | 2018 | 15 | 0.040 |
Why?
| | Homozygote | 1 | 2019 | 187 | 0.040 |
Why?
| | Gastritis | 1 | 2019 | 84 | 0.040 |
Why?
| | Enteritis | 1 | 2019 | 82 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2019 | 274 | 0.040 |
Why?
| | Siblings | 1 | 2019 | 221 | 0.040 |
Why?
| | Time Factors | 1 | 2008 | 6116 | 0.040 |
Why?
| | Quality of Life | 1 | 2008 | 2353 | 0.040 |
Why?
| | Cell Division | 1 | 1999 | 758 | 0.040 |
Why?
| | Vaccines, Synthetic | 1 | 1998 | 124 | 0.040 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 1999 | 688 | 0.040 |
Why?
| | Cytomegalovirus Infections | 1 | 2019 | 180 | 0.030 |
Why?
| | Gastrointestinal Agents | 1 | 2017 | 60 | 0.030 |
Why?
| | Decision Making | 1 | 2023 | 782 | 0.030 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 1998 | 170 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 2018 | 399 | 0.030 |
Why?
| | Glioma | 1 | 1999 | 294 | 0.030 |
Why?
| | Patient Acceptance of Health Care | 1 | 2022 | 681 | 0.030 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2001 | 577 | 0.030 |
Why?
| | Peroxidase | 1 | 2015 | 163 | 0.030 |
Why?
| | In Situ Nick-End Labeling | 1 | 2015 | 119 | 0.030 |
Why?
| | Fibronectins | 1 | 2015 | 108 | 0.030 |
Why?
| | Interleukin-13 | 1 | 2015 | 122 | 0.030 |
Why?
| | Autoantibodies | 1 | 2022 | 1349 | 0.030 |
Why?
| | Constriction, Pathologic | 1 | 2015 | 208 | 0.030 |
Why?
| | NF-kappa B | 1 | 2018 | 641 | 0.030 |
Why?
| | Cell Adhesion Molecules | 1 | 2015 | 168 | 0.030 |
Why?
| | Chemokines | 1 | 2015 | 216 | 0.030 |
Why?
| | Models, Molecular | 1 | 2019 | 1369 | 0.030 |
Why?
| | Self Report | 1 | 2018 | 696 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 1 | 2015 | 397 | 0.030 |
Why?
| | B-Cell Maturation Antigen | 1 | 2013 | 4 | 0.030 |
Why?
| | Immunoglobulin Class Switching | 1 | 2013 | 15 | 0.030 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2014 | 127 | 0.030 |
Why?
| | Eosinophils | 1 | 2015 | 278 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2018 | 4624 | 0.030 |
Why?
| | Collagen | 1 | 2015 | 415 | 0.030 |
Why?
| | Hospitalization | 1 | 2022 | 1752 | 0.030 |
Why?
| | Cell Membrane Permeability | 1 | 2013 | 83 | 0.030 |
Why?
| | Cytidine Deaminase | 1 | 2013 | 58 | 0.030 |
Why?
| | Cell Count | 1 | 2013 | 303 | 0.030 |
Why?
| | Adenocarcinoma | 1 | 1999 | 795 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2015 | 477 | 0.030 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2012 | 49 | 0.030 |
Why?
| | Immunoglobulin M | 1 | 2013 | 246 | 0.020 |
Why?
| | Choroid | 1 | 2012 | 47 | 0.020 |
Why?
| | Prospective Studies | 2 | 2015 | 6220 | 0.020 |
Why?
| | CpG Islands | 1 | 2012 | 118 | 0.020 |
Why?
| | Incidence | 1 | 2018 | 2313 | 0.020 |
Why?
| | Retinal Pigment Epithelium | 1 | 2012 | 58 | 0.020 |
Why?
| | Acetylation | 1 | 2012 | 211 | 0.020 |
Why?
| | Brain Neoplasms | 1 | 1999 | 979 | 0.020 |
Why?
| | Cell Hypoxia | 1 | 2012 | 221 | 0.020 |
Why?
| | Exons | 1 | 2012 | 302 | 0.020 |
Why?
| | RNA Interference | 1 | 2012 | 433 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2017 | 3004 | 0.020 |
Why?
| | Immune Tolerance | 1 | 2012 | 323 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2012 | 740 | 0.020 |
Why?
| | Transforming Growth Factor beta | 1 | 2012 | 448 | 0.020 |
Why?
| | Infant, Premature | 1 | 2013 | 476 | 0.020 |
Why?
| | Immunoglobulin G | 1 | 2013 | 770 | 0.020 |
Why?
| | Drug Design | 1 | 2009 | 148 | 0.020 |
Why?
| | Colorado | 1 | 2018 | 4100 | 0.020 |
Why?
| | B-Lymphocytes | 1 | 2013 | 766 | 0.020 |
Why?
| | Gene Expression | 1 | 2013 | 1421 | 0.020 |
Why?
| | Lung Neoplasms | 1 | 2001 | 2177 | 0.020 |
Why?
| | Interleukin-1 | 1 | 2012 | 966 | 0.020 |
Why?
| | Diet | 1 | 2015 | 1080 | 0.020 |
Why?
| | Mice, Congenic | 1 | 2007 | 21 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2012 | 1629 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 4410 | 0.020 |
Why?
| | Histones | 1 | 2012 | 535 | 0.020 |
Why?
| | Organ Transplantation | 1 | 2009 | 159 | 0.020 |
Why?
| | Drug Delivery Systems | 1 | 2009 | 296 | 0.020 |
Why?
| | Mice, SCID | 1 | 2007 | 314 | 0.020 |
Why?
| | Thymus Gland | 1 | 2007 | 296 | 0.020 |
Why?
| | Oxidative Stress | 1 | 2012 | 1076 | 0.020 |
Why?
| | Communication | 1 | 2011 | 744 | 0.020 |
Why?
| | Young Adult | 1 | 2018 | 10472 | 0.010 |
Why?
| | Adult | 1 | 2022 | 30554 | 0.010 |
Why?
| | Killer Cells, Lymphokine-Activated | 1 | 1999 | 9 | 0.010 |
Why?
| | Neoplasm Transplantation | 1 | 1999 | 228 | 0.010 |
Why?
| | Ouabain | 1 | 1998 | 15 | 0.010 |
Why?
| | Melanoma-Specific Antigens | 1 | 1998 | 2 | 0.010 |
Why?
| | Hybrid Cells | 1 | 1998 | 49 | 0.010 |
Why?
| | Middle Aged | 1 | 2017 | 26738 | 0.010 |
Why?
| | Ultraviolet Rays | 1 | 1998 | 363 | 0.010 |
Why?
| | Neoplasm Proteins | 1 | 1998 | 385 | 0.010 |
Why?
| | Drug Resistance, Neoplasm | 1 | 1998 | 638 | 0.010 |
Why?
| | Vaccination | 1 | 1998 | 1204 | 0.010 |
Why?
|
|
deZoeten's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|